The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1

Ozeren, M; Karahan, SÜLEYMAN; Ozgur, M; Eminagaoglu, S; Unsal, MESUT; Baytan, ŞÜKRÜCAN; Bozkaya, HASAN

doi:10.1111/j.0001-6349.2005.00817.x

The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1

Atıf İçin Kopyala

Ozeren M., Karahan S. C., Ozgur M., Eminagaoglu S., Unsal M. A., Baytan S., ...Daha Fazla

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, cilt.84, sa.10, ss.987-991, 2005 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 84 Sayı: 10
Basım Tarihi: 2005
Doi Numarası: 10.1111/j.0001-6349.2005.00817.x
Dergi Adı: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.987-991
Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Background. Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.